Washington ? Mindful of last year’s flu vaccine shortage, the Food and Drug Administration approved a new shot on Wednesday in an attempt to ensure adequate supplies for the upcoming flu season.

It remains uncertain, however, whether there will be enough shots for all who want them.

The FDA approved the vaccine Fluarix for people 18 and older. The shots, made in Germany by a subsidiary of GlaxoSmithKline, have been available in other countries for years.

A spokesman said the company expects to supply 8 million doses to the U.S. market this flu season, at a price comparable to other flu shots. Flu vaccine typically costs less than $20 a dose.

The government hasn’t yet predicted just how much flu vaccine the nation will have this fall.